APO Research
Talk to an analyst

APO RESEARCH · REPORT

Long-acting Anti-HIV Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Long-acting Anti-HIV Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025170 pages

Choose your research edition.

Industry ResearchLong-acting Anti-HIV Drugs Industry Research Report 2026107 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting Anti-HIV Drugs Industry Growth and Trends Forecast to 203271 pages · $3,450 USDMarket StructureGlobal Long-acting Anti-HIV Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032170 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting Anti-HIV Drugs Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting Anti-HIV Drugs Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Long-acting Anti-HIV Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Long-acting Anti-HIV Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Long-acting Anti-HIV Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Long-acting Anti-HIV Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Long-acting Anti-HIV Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Long-acting Anti-HIV Drugs include Theratechnologies, ViiV Healthcare, Gilead Sciences and Janssen Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Long-acting Anti-HIV Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Long-acting Anti-HIV Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Long-acting Anti-HIV Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Long-acting Anti-HIV Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Long-acting Anti-HIV Drugs Segment by Company

Theratechnologies

ViiV Healthcare

Gilead Sciences

Janssen Pharmaceuticals

Long-acting Anti-HIV Drugs Segment by Type

Single Drug

Combination Preparation

Long-acting Anti-HIV Drugs Segment by Application

HIV Prevention

HIV Treatment

Long-acting Anti-HIV Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting Anti-HIV Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting Anti-HIV Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting Anti-HIV Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Long-acting Anti-HIV Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Long-acting Anti-HIV Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Long-acting Anti-HIV Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Long-acting Anti-HIV Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Long-acting Anti-HIV Drugs Industry Trends Table 2. Long-acting Anti-HIV Drugs Industry Drivers Table 3. Long-acting Anti-HIV Drugs Industry Opportunities and Challenges Table 4. Long-acting Anti-HIV Drugs Industry Restraints Table 5. Global Long-acting Anti-HIV Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Long-acting Anti-HIV Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Long-acting Anti-HIV Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Long-acting Anti-HIV Drugs Sales Market Share by Manufacturers Table 9. Global Long-acting Anti-HIV Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Long-acting Anti-HIV Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Long-acting Anti-HIV Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Long-acting Anti-HIV Drugs Manufacturers, Product Type & Application Table 13. Global Long-acting Anti-HIV Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Long-acting Anti-HIV Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Single Drug Table 17. Major Manufacturers of Combination Preparation Table 18. Global Long-acting Anti-HIV Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Long-acting Anti-HIV Drugs Sales by Type (2021-2026) & (K Units) Table 20. Global Long-acting Anti-HIV Drugs Sales by Type (2027-2032) & (K Units) Table 21. Global Long-acting Anti-HIV Drugs Sales Market Share by Type (2021-2026) Table 22. Global Long-acting Anti-HIV Drugs Sales Market Share by Type (2027-2032) Table 23. Global Long-acting Anti-HIV Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Long-acting Anti-HIV Drugs Revenue by Type (2021-2026) & (K Units) Table 25. Global Long-acting Anti-HIV Drugs Revenue by Type (2027-2032) & (K Units) Table 26. Global Long-acting Anti-HIV Drugs Revenue Market Share by Type (2021-2026) Table 27. Global Long-acting Anti-HIV Drugs Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of HIV Prevention Table 29. Major Manufacturers of HIV Treatment Table 30. Global Long-acting Anti-HIV Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 31. Global Long-acting Anti-HIV Drugs Sales by Application (2021-2026) & (K Units) Table 32. Global Long-acting Anti-HIV Drugs Sales by Application (2027-2032) & (K Units) Table 33. Global Long-acting Anti-HIV Drugs Sales Market Share by Application (2021-2026) Table 34. Global Long-acting Anti-HIV Drugs Sales Market Share by Application (2027-2032) Table 35. Global Long-acting Anti-HIV Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Long-acting Anti-HIV Drugs Revenue by Application (2021-2026) & (K Units) Table 37. Global Long-acting Anti-HIV Drugs Revenue by Application (2027-2032) & (K Units) Table 38. Global Long-acting Anti-HIV Drugs Revenue Market Share by Application (2021-2026) Table 39. Global Long-acting Anti-HIV Drugs Revenue Market Share by Application (2027-2032) Table 40. Global Long-acting Anti-HIV Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 41. Global Long-acting Anti-HIV Drugs Sales by Region (2021-2026) & (K Units) Table 42. Global Long-acting Anti-HIV Drugs Sales Market Share by Region (2021-2026) Table 43. Global Long-acting Anti-HIV Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 44. Global Long-acting Anti-HIV Drugs Sales Forecasted Market Share by Region (2027-2032) Table 45. North America Long-acting Anti-HIV Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 46. North America Long-acting Anti-HIV Drugs Sales by Country (2021-2026) & (K Units) Table 47. North America Long-acting Anti-HIV Drugs Sales by Country (2027-2032) & (K Units) Table 48. Europe Long-acting Anti-HIV Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. Europe Long-acting Anti-HIV Drugs Sales by Country (2021-2026) & (K Units) Table 50. Europe Long-acting Anti-HIV Drugs Sales by Country (2027-2032) & (K Units) Table 51. Asia Pacific Long-acting Anti-HIV Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Asia Pacific Long-acting Anti-HIV Drugs Sales by Country (2021-2026) & (K Units) Table 53. Asia Pacific Long-acting Anti-HIV Drugs Sales by Country (2027-2032) & (K Units) Table 54. South America, Middle East and Africa Long-acting Anti-HIV Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. South America, Middle East and Africa Long-acting Anti-HIV Drugs Sales by Country (2021-2026) & (K Units) Table 56. South America, Middle East and Africa Long-acting Anti-HIV Drugs Sales by Country (2027-2032) & (K Units) Table 57. Global Long-acting Anti-HIV Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Long-acting Anti-HIV Drugs Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Long-acting Anti-HIV Drugs Revenue by Region (2027-2032) & (US$ Million) Table 60. Global Long-acting Anti-HIV Drugs Revenue Market Share by Region (2021-2026) Table 61. Global Long-acting Anti-HIV Drugs Revenue Market Share by Region (2027-2032) Table 62. Theratechnologies Company Information Table 63. Theratechnologies Business Overview Table 64. Theratechnologies Long-acting Anti-HIV Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Theratechnologies Long-acting Anti-HIV Drugs Product Portfolio Table 66. Theratechnologies Recent Development Table 67. ViiV Healthcare Company Information Table 68. ViiV Healthcare Business Overview Table 69. ViiV Healthcare Long-acting Anti-HIV Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. ViiV Healthcare Long-acting Anti-HIV Drugs Product Portfolio Table 71. ViiV Healthcare Recent Development Table 72. Gilead Sciences Company Information Table 73. Gilead Sciences Business Overview Table 74. Gilead Sciences Long-acting Anti-HIV Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Gilead Sciences Long-acting Anti-HIV Drugs Product Portfolio Table 76. Gilead Sciences Recent Development Table 77. Janssen Pharmaceuticals Company Information Table 78. Janssen Pharmaceuticals Business Overview Table 79. Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Product Portfolio Table 81. Janssen Pharmaceuticals Recent Development Table 82. Key Raw Materials Table 83. Raw Materials Key Suppliers Table 84. Long-acting Anti-HIV Drugs Distributors List Table 85. Long-acting Anti-HIV Drugs Customers List Table 86. Research Programs/Design for This Report Table 87. Authors List of This Report Table 88. Secondary Sources Table 89. Primary Sources List of Figures Figure 1. Long-acting Anti-HIV Drugs Product Image Figure 2. Global Long-acting Anti-HIV Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long-acting Anti-HIV Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Long-acting Anti-HIV Drugs Sales (2021-2032) & (K Units) Figure 5. Global Long-acting Anti-HIV Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Long-acting Anti-HIV Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Single Drug Image Figure 9. Combination Preparation Image Figure 10. Global Long-acting Anti-HIV Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Long-acting Anti-HIV Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Long-acting Anti-HIV Drugs Sales Market Share by Type (2021-2032) Figure 13. Global Long-acting Anti-HIV Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Long-acting Anti-HIV Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Long-acting Anti-HIV Drugs Revenue Market Share by Type (2021-2032) Figure 16. HIV Prevention Image Figure 17. HIV Treatment Image Figure 18. Global Long-acting Anti-HIV Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 19. Global Long-acting Anti-HIV Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Long-acting Anti-HIV Drugs Sales Market Share by Application (2021-2032) Figure 21. Global Long-acting Anti-HIV Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Long-acting Anti-HIV Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Long-acting Anti-HIV Drugs Revenue Market Share by Application (2021-2032) Figure 24. North America Long-acting Anti-HIV Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 25. North America Long-acting Anti-HIV Drugs Sales Market Share by Country (2021-2032) Figure 26. U.S. Long-acting Anti-HIV Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 27. Canada Long-acting Anti-HIV Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Mexico Long-acting Anti-HIV Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Europe Long-acting Anti-HIV Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Long-acting Anti-HIV Drugs Sales Market Share by Country (2021-2032) Figure 31. Germany Long-acting Anti-HIV Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 32. France Long-acting Anti-HIV Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. U.K. Long-acting Anti-HIV Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Italy Long-acting Anti-HIV Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Netherlands Long-acting Anti-HIV Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Asia Pacific Long-acting Anti-HIV Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Long-acting Anti-HIV Drugs Sales Market Share by Country (2021-2032) Figure 38. China Long-acting Anti-HIV Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Japan Long-acting Anti-HIV Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. South Korea Long-acting Anti-HIV Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Southeast Asia Long-acting Anti-HIV Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. India Long-acting Anti-HIV Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Australia Long-acting Anti-HIV Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South America, Middle East and Africa Long-acting Anti-HIV Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Long-acting Anti-HIV Drugs Sales Market Share by Country (2021-2032) Figure 46. Brazil Long-acting Anti-HIV Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South Africa Long-acting Anti-HIV Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Saudi Arabia Long-acting Anti-HIV Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Turkey Long-acting Anti-HIV Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Argentina Long-acting Anti-HIV Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. UAE Long-acting Anti-HIV Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Egypt Long-acting Anti-HIV Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Chile Long-acting Anti-HIV Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Global Long-acting Anti-HIV Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global Long-acting Anti-HIV Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America Long-acting Anti-HIV Drugs Revenue (2021-2032) & (US$ Million) Figure 57. North America Long-acting Anti-HIV Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe Long-acting Anti-HIV Drugs Revenue (2021-2032) & (US$ Million) Figure 59. Europe Long-acting Anti-HIV Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific Long-acting Anti-HIV Drugs Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific Long-acting Anti-HIV Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa Long-acting Anti-HIV Drugs Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa Long-acting Anti-HIV Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Long-acting Anti-HIV Drugs Value Chain Figure 65. Manufacturing Cost Structure Figure 66. Long-acting Anti-HIV Drugs Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Single Drug
  • Combination Preparation
Applications
  • HIV Prevention
  • HIV Treatment
Companies covered
  • Theratechnologies
  • ViiV Healthcare
  • Gilead Sciences
  • Janssen Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Long-acting Anti-HIV Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Long-acting Anti-HIV Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Long-acting Anti-HIV Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Long-acting Anti-HIV Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Long-acting Anti-HIV Drugs Market Dynamics
  1. 2.1 Long-acting Anti-HIV Drugs Industry Trends
  2. 2.2 Long-acting Anti-HIV Drugs Industry Drivers
  3. 2.3 Long-acting Anti-HIV Drugs Industry Opportunities and Challenges
  4. 2.4 Long-acting Anti-HIV Drugs Industry Restraints
3 Long-acting Anti-HIV Drugs Market by Manufacturers
  1. 3.1 Global Long-acting Anti-HIV Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Long-acting Anti-HIV Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Long-acting Anti-HIV Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Long-acting Anti-HIV Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Long-acting Anti-HIV Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Long-acting Anti-HIV Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Long-acting Anti-HIV Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Long-acting Anti-HIV Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Long-acting Anti-HIV Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Long-acting Anti-HIV Drugs Tier 1, Tier 2, and Tier 3
4 Long-acting Anti-HIV Drugs Market by Type
  1. 4.1 Long-acting Anti-HIV Drugs Type Introduction
  2. 4.1.1 Single Drug
  3. 4.1.2 Combination Preparation
  4. 4.2 Global Long-acting Anti-HIV Drugs Sales by Type
  5. 4.2.1 Global Long-acting Anti-HIV Drugs Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Long-acting Anti-HIV Drugs Sales by Type (2021-2032)
  7. 4.2.3 Global Long-acting Anti-HIV Drugs Sales Market Share by Type (2021-2032)
  8. 4.3 Global Long-acting Anti-HIV Drugs Revenue by Type
  9. 4.3.1 Global Long-acting Anti-HIV Drugs Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Long-acting Anti-HIV Drugs Revenue by Type (2021-2032)
  11. 4.3.3 Global Long-acting Anti-HIV Drugs Revenue Market Share by Type (2021-2032)
5 Long-acting Anti-HIV Drugs Market by Application
  1. 5.1 Long-acting Anti-HIV Drugs Application Introduction
  2. 5.1.1 HIV Prevention
  3. 5.1.2 HIV Treatment
  4. 5.2 Global Long-acting Anti-HIV Drugs Sales by Application
  5. 5.2.1 Global Long-acting Anti-HIV Drugs Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Long-acting Anti-HIV Drugs Sales by Application (2021-2032)
  7. 5.2.3 Global Long-acting Anti-HIV Drugs Sales Market Share by Application (2021-2032)
  8. 5.3 Global Long-acting Anti-HIV Drugs Revenue by Application
  9. 5.3.1 Global Long-acting Anti-HIV Drugs Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Long-acting Anti-HIV Drugs Revenue by Application (2021-2032)
  11. 5.3.3 Global Long-acting Anti-HIV Drugs Revenue Market Share by Application (2021-2032)
6 Global Long-acting Anti-HIV Drugs Sales by Region
  1. 6.1 Global Long-acting Anti-HIV Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Long-acting Anti-HIV Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Long-acting Anti-HIV Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Long-acting Anti-HIV Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Long-acting Anti-HIV Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Long-acting Anti-HIV Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Long-acting Anti-HIV Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Long-acting Anti-HIV Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Long-acting Anti-HIV Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Long-acting Anti-HIV Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Long-acting Anti-HIV Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Long-acting Anti-HIV Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Long-acting Anti-HIV Drugs Revenue by Region
  1. 7.1 Global Long-acting Anti-HIV Drugs Revenue by Region
  2. 7.1.1 Global Long-acting Anti-HIV Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Long-acting Anti-HIV Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Long-acting Anti-HIV Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Long-acting Anti-HIV Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Long-acting Anti-HIV Drugs Revenue (2021-2032)
  8. 7.2.2 North America Long-acting Anti-HIV Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Long-acting Anti-HIV Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Long-acting Anti-HIV Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Long-acting Anti-HIV Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Long-acting Anti-HIV Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Long-acting Anti-HIV Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Long-acting Anti-HIV Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Theratechnologies
  2. 8.1.1 Theratechnologies Company Information
  3. 8.1.2 Theratechnologies Business Overview
  4. 8.1.3 Theratechnologies Long-acting Anti-HIV Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Theratechnologies Long-acting Anti-HIV Drugs Product Portfolio
  6. 8.1.5 Theratechnologies Recent Developments
  7. 8.2 ViiV Healthcare
  8. 8.2.1 ViiV Healthcare Company Information
  9. 8.2.2 ViiV Healthcare Business Overview
  10. 8.2.3 ViiV Healthcare Long-acting Anti-HIV Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 ViiV Healthcare Long-acting Anti-HIV Drugs Product Portfolio
  12. 8.2.5 ViiV Healthcare Recent Developments
  13. 8.3 Gilead Sciences
  14. 8.3.1 Gilead Sciences Company Information
  15. 8.3.2 Gilead Sciences Business Overview
  16. 8.3.3 Gilead Sciences Long-acting Anti-HIV Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Gilead Sciences Long-acting Anti-HIV Drugs Product Portfolio
  18. 8.3.5 Gilead Sciences Recent Developments
  19. 8.4 Janssen Pharmaceuticals
  20. 8.4.1 Janssen Pharmaceuticals Company Information
  21. 8.4.2 Janssen Pharmaceuticals Business Overview
  22. 8.4.3 Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Product Portfolio
  24. 8.4.5 Janssen Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Long-acting Anti-HIV Drugs Value Chain Analysis
  2. 9.1.1 Long-acting Anti-HIV Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Long-acting Anti-HIV Drugs Production Mode & Process
  6. 9.2 Long-acting Anti-HIV Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Long-acting Anti-HIV Drugs Distributors
  9. 9.2.3 Long-acting Anti-HIV Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst